Patents | Published:

Prior art considerations when patenting DNA sequences

Nature Biotechnologyvolume 14pages13091310 (1996) | Download Citation

Subjects

Prior disclosure of corresponding protein sequences or uncharacterized DNA sequences may impact your chances to patent a newly discovered DNA.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Amgen Inc. v. Chugai Pharmaceutical Co., Ltd., 9 USPQ2d 1833 (D. Mass. 1989); 18 USPQ2d 1016 (Fed. Cir. 1991).

  2. 2

    In re Bell 26 USPQ2d 1529 (Fed. Cir. 1993).

  3. 3

    In re Deuel 34 USPQ2d 1210 (Fed. Cir. 1995).

  4. 4

    In re Deuel, 34 USPQ2d at 1215.

Download references

Author information

Affiliations

  1. Patent attorney at Novo Nordisk of North America, 405 Lexington Ave., Suite 6400, New York, NY, 10017

    • Cheryl H. Agris

Authors

  1. Search for Cheryl H. Agris in:

About this article

Publication history

Issue Date

DOI

https://doi.org/10.1038/nbt1096-1309

Further reading